Piramal Pharma Limited's Ahmedabad facility successfully completes USFDA Pre-Approval Inspection

Piramal Pharma Limited has announced that the US FDA conducted a Pre-Approval Inspection ('PAI') of Piramal Pharma Limited's PPDS Ahmedabad facility from 10th July 2024 to 12th July, 2024.

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to our high-end analytical capabilities to our customers for their clinical and commercial batches from an FDA approved site.

The Company remains committed to maintain the highest standards of compliance.

Shares of Piramal Pharma Limited was last trading in BSE at Rs. 151.15 as compared to the previous close of Rs. 151.60. The total number of shares traded during the day was 160573 in over 2824 trades.

The stock hit an intraday high of Rs. 152.40 and intraday low of 150.00. The net turnover during the day was Rs. 24284149.00.

Source : Equity Bulls

Keywords

PiramalPharma PPLPHARMA INE0DK501011 Pharmaceuticals PreApprovalInspection USFDA AhmedabadFacility